We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population.
- Authors
Juurlink, D N; Gomes, T; Shah, B R; Mamdani, M M
- Abstract
Sulphonylureas promote insulin release by inhibiting pancreatic potassium channels. Older sulphonylureas such as glyburide (glibenclamide), but not newer ones such as gliclazide, antagonize similar channels in myocardium, interfering with the protective effects of ischaemic preconditioning. Whether this imparts a higher risk of adverse cardiac events is unknown.
- Publication
Diabetic medicine : a journal of the British Diabetic Association, 2012, Vol 29, Issue 12, p1524
- ISSN
1464-5491
- Publication type
Journal Article
- DOI
10.1111/j.1464-5491.2012.03772.x